anthonyyazdaniml/CT-ADE-SOC huggingface dataset:
Intervention: Dextromethorphan
Trial phase: Phase 2
ATC code: N07XX59 | R05DA09
SMILES: COc1ccc2c(c1)C13CCCCC1C(C2)N(C)CC3
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 25
Group description: 100% of maximum tolerated dose of dextromethorphan; dose was administered for a period of 28 days, and on day 21, subjects traveled to the study site to undergo additional study procedures.
Eligibility criteria:
Inclusion Criteria:

Healthy male or female adults, age 18 to 70 with central neuropathic pain for a minimum of 3 months following SCI as confirmed by neurologic evaluation, with an average pain intensity score of at least moderate over at least 50% of the day for the 7 days prior to the screening visit and over the 7 days prior to starting study medication.
Subjects used no medication or a stabilized medication regimen for chronic and well-controlled medical conditions

Serum laboratory examination obtained at study entry:

Liver function tests (albumin within 20% of normal, SGOT/SGPT within 50% of normal).
For women of childbearing age: negative serum beta HCG.
Postmenopausal women, or be physically incapable of childbearing, or be practicing an acceptable method of birth control.
Normal cognitive function.
Normal communicative ability (English).
Ability to demonstrate competence in recording five times daily in pain diary for 1 week (with 100% compliance), and in completing required questionnaires.
Signed informed consent.

Exclusion Criteria:

Pregnancy or breast-feeding.
Renal or hepatic dysfunction.
Significant cardiac disease (e.g. MI within 1 year).
Signs or symptoms of central neurological disorder, excluding SCI.
Severe psychological disorder requiring treatment.
Concurrent use of monoamine oxidase inhibitors within 2 weeks prior to study entry.
Use of known CYP2D6 (but not CYP3A4) inhibitors or inducers.
History of hypersensitivity or intolerance to dextromethorphan or lidocaine.
Chronic substance abuse, including alcohol.
Participation in a study of an investigational drug or device within 30 days prior to screening for this study.
Poor metabolizer of P450 2D6 substrates.
Intervention: Mifepristone
Trial phase: Phase 3
ATC code: G03XB01 | G03XB51
SMILES: [H][C@@]12CC[C@@](O)(C#CC)[C@@]1(C)C[C@H](c1ccc(N(C)C)cc1)C1=C3CCC(=O)C=C3CC[C@]12[H]
Sex: Female
Age groups: Adult
Healthy volunteers: No
Participants at risk: 50
Group description: Mifepristone 200 mg PO given 20-24 hours prior to procedure, misoprostol 400 mcg given 2 hours prior to procedure

Mifepristone: 200 mg po 20-24 hours prior to the procedure
Eligibility criteria:
Inclusion Criteria:

Women 18-50 years of age undergoing surgical termination of pregnancy
English or Spanish speaking
Gestational age between 15 and 18 weeks gestation on day of abortion (inclusive), by ultrasound dating
Eligible for a dilation and evacuation abortion with local anesthesia and sedation
Ultrasound for dating purposes done within the last two weeks

Exclusion Criteria:

Intrauterine infection
Fetal demise
Ruptured membranes
Multiple gestation
Uterine anomaly or significant distortion of the uterus with fibroids
BMI greater than 45
Inability to place osmotic dilators
Active substance abuse or intoxication
Adrenal failure, chronic corticosteroid use, anticoagulant usage
Severe cervicitis, until treated and resolved
Prior Cesarean section
Intervention: Sertraline
Trial phase: Not Applicable
ATC code: N06AB06
SMILES: CN[C@H]1CC[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc21
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 35
Group description: This arm received treatment of Sertraline. Sertraline: Starting dose 25mg/day for 1 week, then increasing to 50mg/day, add on 50mg each time when the depressive symptoms are not improved, at 2-week intervals. Maximum: 200mg/day. Maintenance: lowest effective dose.
Eligibility criteria:
Inclusion Criteria:

Patients between 35 and 75 years of age from the outpatients clinic in Department of Neurology, the Second Affiliated Hospital, School of Medicine, Zhejiang University.
All patients should have a confirmed diagnosis of PD according to Brain Bank Criteria.
Diagnosed to be major depression episode according to DSM-IV,
Mini Mental State Examination (MMSE) exclude dementia.

Exclusion Criteria:

Mini-Mental State Examination (MMSE) demonstrate dementia
Any current DSM-IV Axis I diagnosis other than a depressive or anxiety disorder.
History of psychosis or hallucinations or under treatment with atypical neuroleptics.
Treatment-resistant depression. Treatment-resistant depression (TRD) occurs when a patient with unipolar depression fails to respond to adequate antidepressant therapy.
Pregnancy or lactation.
Concomitant use in patients taking monoamine oxidase inhibitors (MAOIs).
Concomitant use in patients taking pimozide.
Intervention: Iloprost
Trial phase: Phase 2
ATC code: B01AC11
SMILES: CC#CCC(C)C(O)C=CC1C(O)CC2CC(=CCCCC(=O)O)CC21
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 2
Group description: single dose inhalation using the power disc-6 with I-neb AAD system

Iloprost: 5ug dose of inhaled iloprost (20ug/mL solution) administered 6 to 9 times per day for 4 weeks
Eligibility criteria:
Inclusion Criteria:

Signed informed consent prior to initiation of any study mandated procedure
Male or female ≥ 40 and ≤ 75 years of age
Women of childbearing potential1 must use a reliable method of contraception
Clinical diagnosis of moderate to severe COPD, with an obstructive pattern on pulmonary function tests
Current or past smokers of ≥ 10 pack years
Ability to perform exercise testing without supplemental oxygen (in the best opinion of the investigator)
Confirmed pulmonary hypertension by right heart catheterization (RHC)

Exclusion Criteria:

Other causes of pulmonary hypertension than COPD
BMI > 35 kg/m2
Conditions considered as contraindications for cardiopulmonary exercise testing (CPET) and/or inability to pedal on a cycle ergometer
Pregnant or nursing
Currently (within 30 days prior to RHC) taking specific pulmonary arterial hypertension (PAH) therapy (e.g., bosentan, ambrisentan, tadalafil, sildenafil, epoprostenol, treprostinil, iloprost, beraprost)
Participation in any other clinical trial, except observational, or receipt of an investigational product within 30 days prior to RHC visit
Known concomitant life-threatening disease with a life expectancy < 12 months
Known hypersensitivity to iloprost or any of the excipients of the drug formulations
Intervention: Dexmedetomidine Hydrochloride
Trial phase: Phase 3
SMILES: Cc1cccc(C(C)c2cnc[nH]2)c1C.Cl
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 23
Group description: 0.4 mcg/kg/hr 10min Initial dose + 0.2-0.7 mcg/kg/hr Maintenance dose
Eligibility criteria:
Inclusion Criteria:

Patient has signed and dated the Informed Consent after the study had been fully explained.
Patient is male or female, at least 20 years of age when the Informed Consent is obtained.
American Society for Anesthesiologists (ASA) I to III Class.
Patient who requires sedation during the elective surgery which requires ≥30mins (expected time) without intubation under monitored sedation care.
Patient undergoing a surgery requiring epidural or spinal anesthesia

Exclusion Criteria:

Patient who underwent general anesthesia within 7 days, or who received other study drugs within 30 days from the date of consent.
Patient with <92% SpO2, at the physical examination prior to the study drug administration, or ventilatory failure which requires intubation or Laryngeal Mask.
Patient with central nervous system pathology which may lead to increased intracranial pressure, uncontrolled seizures, psychiatric disorder which may be confused with the response to sedation treatment.
Patient who require general anesthesia.
Patient who receives treatment by alpha-2 agonists or alpha-2 antagonists within seven days of scheduled surgery or procedure.
Patient in whom opioids, DA-9501 or other alpha-2 agonists, or drugs which may be used in the study are contraindicated.
Patient diagnosed with unstable angina or acute myocardiac infarction within 6 weeks from the date of consent.
Patient whose heart rate is <60 bpm, systolic blood pressure is <90 mmHg by the physical examination prior to the study drug administration.
Patient has third degree heart block, unless the patient has a pacemaker or transverse pacing wires are in place.
Patient who has experienced an increase in alanine transaminase (ALT) and / or aspartate aminotransferase (AST) more than double the upper normal limit within 2 months of the date of consent, or who has a history of liver insufficiency.
Pregnant or lactating woman.
In the Investigator's or subinvestigator's opinion, the patient has any symptom or condition which might increase risk to the patient by conducting the study or preclude obtaining satisfactory study data
Intervention: Dexmedetomidine Hydrochloride
Trial phase: Phase 3
SMILES: Cc1cccc(C(C)c2cnc[nH]2)c1C.Cl
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 24
Group description: 1.5 mcg/kg/hr 10min Initial dose + 0.2-0.7 mcg/kg/hr Maintenance dose
Eligibility criteria:
Inclusion Criteria:

Patient has signed and dated the Informed Consent after the study had been fully explained.
Patient is male or female, at least 20 years of age when the Informed Consent is obtained.
American Society for Anesthesiologists (ASA) I to III Class.
Patient who requires sedation during the elective surgery which requires ≥30mins (expected time) without intubation under monitored sedation care.
Patient undergoing a surgery requiring epidural or spinal anesthesia

Exclusion Criteria:

Patient who underwent general anesthesia within 7 days, or who received other study drugs within 30 days from the date of consent.
Patient with <92% SpO2, at the physical examination prior to the study drug administration, or ventilatory failure which requires intubation or Laryngeal Mask.
Patient with central nervous system pathology which may lead to increased intracranial pressure, uncontrolled seizures, psychiatric disorder which may be confused with the response to sedation treatment.
Patient who require general anesthesia.
Patient who receives treatment by alpha-2 agonists or alpha-2 antagonists within seven days of scheduled surgery or procedure.
Patient in whom opioids, DA-9501 or other alpha-2 agonists, or drugs which may be used in the study are contraindicated.
Patient diagnosed with unstable angina or acute myocardiac infarction within 6 weeks from the date of consent.
Patient whose heart rate is <60 bpm, systolic blood pressure is <90 mmHg by the physical examination prior to the study drug administration.
Patient has third degree heart block, unless the patient has a pacemaker or transverse pacing wires are in place.
Patient who has experienced an increase in alanine transaminase (ALT) and / or aspartate aminotransferase (AST) more than double the upper normal limit within 2 months of the date of consent, or who has a history of liver insufficiency.
Pregnant or lactating woman.
In the Investigator's or subinvestigator's opinion, the patient has any symptom or condition which might increase risk to the patient by conducting the study or preclude obtaining satisfactory study data
Intervention: Dexmedetomidine Hydrochloride
Trial phase: Phase 3
SMILES: Cc1cccc(C(C)c2cnc[nH]2)c1C.Cl
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 25
Group description: 3 mcg/kg/hr 10min Initial dose + 0.2-0.7 mcg/kg/hr Maintenance dose
Eligibility criteria:
Inclusion Criteria:

Patient has signed and dated the Informed Consent after the study had been fully explained.
Patient is male or female, at least 20 years of age when the Informed Consent is obtained.
American Society for Anesthesiologists (ASA) I to III Class.
Patient who requires sedation during the elective surgery which requires ≥30mins (expected time) without intubation under monitored sedation care.
Patient undergoing a surgery requiring epidural or spinal anesthesia

Exclusion Criteria:

Patient who underwent general anesthesia within 7 days, or who received other study drugs within 30 days from the date of consent.
Patient with <92% SpO2, at the physical examination prior to the study drug administration, or ventilatory failure which requires intubation or Laryngeal Mask.
Patient with central nervous system pathology which may lead to increased intracranial pressure, uncontrolled seizures, psychiatric disorder which may be confused with the response to sedation treatment.
Patient who require general anesthesia.
Patient who receives treatment by alpha-2 agonists or alpha-2 antagonists within seven days of scheduled surgery or procedure.
Patient in whom opioids, DA-9501 or other alpha-2 agonists, or drugs which may be used in the study are contraindicated.
Patient diagnosed with unstable angina or acute myocardiac infarction within 6 weeks from the date of consent.
Patient whose heart rate is <60 bpm, systolic blood pressure is <90 mmHg by the physical examination prior to the study drug administration.
Patient has third degree heart block, unless the patient has a pacemaker or transverse pacing wires are in place.
Patient who has experienced an increase in alanine transaminase (ALT) and / or aspartate aminotransferase (AST) more than double the upper normal limit within 2 months of the date of consent, or who has a history of liver insufficiency.
Pregnant or lactating woman.
In the Investigator's or subinvestigator's opinion, the patient has any symptom or condition which might increase risk to the patient by conducting the study or preclude obtaining satisfactory study data
Intervention: Dexmedetomidine Hydrochloride
Trial phase: Phase 3
SMILES: Cc1cccc(C(C)c2cnc[nH]2)c1C.Cl
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 25
Group description: 6 mcg/kg/hr 10min Initial dose + 0.2-0.7 mcg/kg/hr Maintenance dose
Eligibility criteria:
Inclusion Criteria:

Patient has signed and dated the Informed Consent after the study had been fully explained.
Patient is male or female, at least 20 years of age when the Informed Consent is obtained.
American Society for Anesthesiologists (ASA) I to III Class.
Patient who requires sedation during the elective surgery which requires ≥30mins (expected time) without intubation under monitored sedation care.
Patient undergoing a surgery requiring epidural or spinal anesthesia

Exclusion Criteria:

Patient who underwent general anesthesia within 7 days, or who received other study drugs within 30 days from the date of consent.
Patient with <92% SpO2, at the physical examination prior to the study drug administration, or ventilatory failure which requires intubation or Laryngeal Mask.
Patient with central nervous system pathology which may lead to increased intracranial pressure, uncontrolled seizures, psychiatric disorder which may be confused with the response to sedation treatment.
Patient who require general anesthesia.
Patient who receives treatment by alpha-2 agonists or alpha-2 antagonists within seven days of scheduled surgery or procedure.
Patient in whom opioids, DA-9501 or other alpha-2 agonists, or drugs which may be used in the study are contraindicated.
Patient diagnosed with unstable angina or acute myocardiac infarction within 6 weeks from the date of consent.
Patient whose heart rate is <60 bpm, systolic blood pressure is <90 mmHg by the physical examination prior to the study drug administration.
Patient has third degree heart block, unless the patient has a pacemaker or transverse pacing wires are in place.
Patient who has experienced an increase in alanine transaminase (ALT) and / or aspartate aminotransferase (AST) more than double the upper normal limit within 2 months of the date of consent, or who has a history of liver insufficiency.
Pregnant or lactating woman.
In the Investigator's or subinvestigator's opinion, the patient has any symptom or condition which might increase risk to the patient by conducting the study or preclude obtaining satisfactory study data
Intervention: Letrozole
Trial phase: Phase 2
ATC code: L02BG04
SMILES: N#Cc1ccc(C(c2ccc(C#N)cc2)n2cncn2)cc1
Sex: Female
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 90
Group description: Protocol Therapy will consist of 6 months of letrozole, administered orally at a dose of 2.5 mg/day. Patients will have a bilateral MRI for disease evaluation at months 3 and 6.
Eligibility criteria:
Eligibility Criteria:

Histologic documentation: Pathologic confirmation of ductal carcinoma in situ (DCIS) of the female breast without invasive cancer, with diagnosis rendered on core biopsy only, completed within 60 days before registration. Patients diagnosed with DCIS on the basis of surgical biopsy are not eligible for this study.

Patients with microinvasion on diagnostic core biopsy, defined as tumor ≤ 1 mm in greatest dimension, will be allowed to participate.
All patients must have a clip placed, either at the time of the diagnostic biopsy or at the time of the baseline MRI prior to the start of treatment.
Tissue samples: Patient has diagnostic tissue available for correlative studies.
Clinical stage: Tis or T1mi N0, M0
Hormone receptor status: DCIS must express estrogen and/or progesterone receptor, as determined by immunohistochemical methods on the diagnostic pathology sample, according to the local institution's standard protocol. Greater than or equal to 1% cells will be considered to be positive.

Menopausal status: Patients must be postmenopausal defined as:

Age ≥ 55 years and one year or more of amenorrhea
Age < 55 years and one year or more amenorrhea, with an estradiol assay < 20pg/ml
Surgical menopause with bilateral oophorectomy (at least 28 days must elapse from surgery to time of study registration)

The use of GnRH analogs to achieve post menopausal status is not allowed.

Prior treatment:

No prior surgical excision in the index breast for current DCIS diagnosis of DCIS
Any exogenous hormone therapy must be completed 4 weeks prior to registration
Any patients with a history of tamoxifen or raloxifene use within two years of current DCIS diagnosis are not eligible
No prior neoadjuvant/adjuvant therapy for current DCIS diagnosis
Contraindication to MRI: No contraindications to breast MRI

Measurable disease: Mammographic extent of calcifications must be accurately measurable in at least one dimension with each lesion ≥ 1 cm and ≤ 7 cm

DCIS must be visible on MRI based on central review.
Patients with palpable DCIS or adenopathy are not eligible to participate.
Patients with multifocal or bilateral disease are eligible.
History of osteoporosis: Women diagnosed with osteoporosis may participate in this trial provided they are receiving appropriate therapy or if they have declined therapy.
Age: Patients ≥ 18 years of age
Performance Status: ECOG performance status 0 or 1
Pregnancy/nursing status: Not pregnant or nursing

Required Initial Laboratory Values:

ANC ≥ 1,000/μL
Platelet count ≥ 100,000/μL
Serum creatinine ≤ 1.7 mg/dL
Bilirubin ≤ 2.0 mg/dL
AST/ALT ≤ 2.5 times upper limit of normal
Serum estradiol level assay < 20 pg/mL *Required for patients < 55 years of age and one year or more of amenorrhea
Intervention: Dapagliflozin
Trial phase: Not Applicable
ATC code: A10BD15 | A10BD21 | A10BD25 | A10BK01
SMILES: CCOc1ccc(Cc2cc([C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)ccc2Cl)cc1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 18
Group description: Interventional arm

Dapagliflozin: Treatment arm, 10 mg per day for 2 weeks
Eligibility criteria:
Inclusion Criteria:

T2DM
Drug Naive Or On Oral Therapy

Exclusion Criteria:

Insulin Treatment
Major Organ Disease
Intervention: Maraciclatide tc-99m
Trial phase: Phase 2
SMILES: CC(=NO)C(C)(C)NCCC(CCNC(=O)CCCC(=O)NCCCCC1NC(=O)CSCC(C(=O)NCCOCCOCCOCCNC(=O)COCC(N)=O)NC(=O)C(Cc2ccccc2)NC(=O)C2CSSCC(NC1=O)C(=O)NC(CCCN=C(N)N)C(=O)NCC(=O)NC(CC(=O)O)C(=O)N2)CCNC(C)(C)C(C)=NO.[Tc]
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 4
Group description: The nominal activity of a single administration of Tc88m maraciclatide was 925 megabecquerels (MBq) (25 millicures).
Eligibility criteria:
Inclusion Criteria:

The subject is between 18 and 80 years of age.
The subject was diagnosed with DM type 2 based upon accepted clinical criteria and currently takes at least one diabetes medication.
For HF subjects: The subject was diagnosed with HF with preserved EF within the previous 1 year, at which time LVEF was determined to be ≥45%.
For comparison subjects: The subject was determined to have diastolic dysfunction on EKG within the previous year and currently has no signs or symptoms of HF.
The subject has been clinically stable for at least 7 days prior to the study imaging procedures (e.g., not experiencing continuing chest pain, hemodynamic instability, worsening HF symptoms, or clinically significant arrhythmia).

Exclusion Criteria:

The subject had an acute myocardial infarction within the past 30 days.
The subject had a cardiac revascularization (e.g., percutaneous transluminal coronary angiography [PTCA], percutaneous coronary intervention (PCI), or coronary artery bypass graft [CABG]) within the past 30 days.
The subject has severe renal dysfunction.
The subject is claustrophobic or has a movement disorder that prevents him/her from lying still in a supine position for up to 20 minutes at a time.
The subject has participated in a research study using ionizing radiation in the previous 12 months.
Intervention: Nesiritide
Trial phase: Phase 2
ATC code: C01DX19
SMILES: CCC(C)C1NC(=O)C(CCCNC(=N)N)NC(=O)C(CC(=O)O)NC(=O)C(CCSC)NC(=O)C(CCCCN)NC(=O)C(CCCNC(=N)N)NC(=O)CNC(=O)C(Cc2ccccc2)NC(=O)C(NC(=O)CNC(=O)C(CO)NC(=O)CNC(=O)C(CCC(N)=O)NC(=O)C(NC(=O)C(CCSC)NC(=O)C(CCCCN)NC(=O)C2CCCN2C(=O)C(N)CO)C(C)C)CSSCC(C(=O)NC(CCCCN)C(=O)NC(C(=O)NC(CC(C)C)C(=O)NC(CCCNC(=N)N)C(=O)NC(CCCNC(=N)N)C(=O)NC(Cc2c[nH]cn2)C(=O)O)C(C)C)NC(=O)CNC(=O)C(CC(C)C)NC(=O)CNC(=O)C(CO)NC(=O)C(CO)NC(=O)C(CO)NC(=O)C(CO)NC1=O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 14
Group description: infuses at 0.01 MCG (micrograms)/KG (kilograms)/min (minute) for 48 hours

Nesiritide: infuses at 0.01MCG/KG/min for 48 hours
Eligibility criteria:
Inclusion Criteria:

Patients undergoing surgery on their aortic arch, ascending aorta, or having aortic valve or mitral valve surgery
Baseline MDRD (modification of diet in renal disease) calculated GFR (Glomerular Filtration Rate) 30-90 ml/min.
Signed Informed Consent

Exclusion Criteria:

Age <18 or >80
Ejection Fraction <30%.
Presence of endocarditis or other infection.
Presence or anticipated use of an intra-aortic balloon pump.
History of an organ transplant.
History of an adverse reaction to nesiritide.
Surgery performed without cardiopulmonary bypass.
Receiving Aprotinin
Dopamine administered in doses <5 mcg /kg min.
Women of child bearing potential or pregnant or breastfeeding.
Participation in any other investigational trial
Jehovah Witness
Bleeding Disorder
Active Endocarditis